These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 12886829

  • 21. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
    Bargiggia S, Thorburn D, Anderloni A, Ardizzone S, Giorgi A, Bianchi Porro G, Parente F.
    Aliment Pharmacol Ther; 2005 Aug 01; 22(3):209-15. PubMed ID: 16091058
    [Abstract] [Full Text] [Related]

  • 22. Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy.
    Tromm A, Greving I, Griga T, Mankel K, Hüppe D.
    Z Gastroenterol; 2000 Feb 01; 38(2):159-64. PubMed ID: 10721171
    [Abstract] [Full Text] [Related]

  • 23. [Autoimmune hemolytic anemia induced by alpha-interferon therapy in a case of IgG-kappa type multiple myeloma].
    Onoda K, Takai K, Sanada M, Aoki S, Watanabe T.
    Rinsho Ketsueki; 1992 Jun 01; 33(6):844-6. PubMed ID: 1433929
    [Abstract] [Full Text] [Related]

  • 24. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases.
    Ramos-Casals M, García-Carrasco M, López-Medrano F, Trejo O, Forns X, López-Guillermo A, Muñoz C, Ingelmo M, Font J.
    Medicine (Baltimore); 2003 Mar 01; 82(2):87-96. PubMed ID: 12640185
    [Abstract] [Full Text] [Related]

  • 25. Pericarditis due to interferon-alpha therapy during treatment for chronic hepatitis C.
    Gressens B, Gohy P.
    Acta Gastroenterol Belg; 2004 Mar 01; 67(3):301-2. PubMed ID: 15587340
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
    Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Bellomo G, Belloni G, Grisorio B, Annese M, Bacca D, Francavilla R, Rizzo G, Barbarini G.
    Am J Gastroenterol; 1998 Dec 01; 93(12):2445-51. PubMed ID: 9860407
    [Abstract] [Full Text] [Related]

  • 30. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T, Farkas A, Tolvaj G, Horváth G.
    Orv Hetil; 2006 Feb 19; 147(7):321-4. PubMed ID: 17489160
    [Abstract] [Full Text] [Related]

  • 31. Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C.
    McHutchison JG, Patel K, Schiff ER, Gitlin N, Mur RE, Everson GT, Carithers RL, Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK, International Hepatitis Interventional Therapy Group.
    Aliment Pharmacol Ther; 2008 Mar 01; 27(5):422-32. PubMed ID: 18081733
    [Abstract] [Full Text] [Related]

  • 32. Pernicious anemia during IFN-alpha treatment for chronic hepatitis C.
    Borgia G, Reynaud L, Gentile I, Borrelli F, Cerini R, Ciampi R, Piazza M.
    J Interferon Cytokine Res; 2003 Jan 01; 23(1):11-2. PubMed ID: 12639294
    [Abstract] [Full Text] [Related]

  • 33. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
    Berardi S, Lodato F, Gramenzi A, D'Errico A, Lenzi M, Bontadini A, Morelli MC, Tamè MR, Piscaglia F, Biselli M, Sama C, Mazzella G, Pinna AD, Grazi G, Bernardi M, Andreone P.
    Gut; 2007 Feb 01; 56(2):237-42. PubMed ID: 16798778
    [Abstract] [Full Text] [Related]

  • 34. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.
    Bräu N, Rodriguez-Torres M, Prokupek D, Bonacini M, Giffen CA, Smith JJ, Frost KR, Kostman JR.
    Hepatology; 2004 Apr 01; 39(4):989-98. PubMed ID: 15057903
    [Abstract] [Full Text] [Related]

  • 35. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC, Bacon BR, Goldin RD.
    Hepatology; 1998 Apr 01; 27(4):1121-7. PubMed ID: 9537453
    [Abstract] [Full Text] [Related]

  • 36. Factors contributing to ribavirin-induced anemia.
    Nomura H, Tanimoto H, Kajiwara E, Shimono J, Maruyama T, Yamashita N, Nagano M, Higashi M, Mukai T, Matsui Y, Hayashi J, Kashiwagi S, Ishibashi H.
    J Gastroenterol Hepatol; 2004 Nov 01; 19(11):1312-7. PubMed ID: 15482540
    [Abstract] [Full Text] [Related]

  • 37. Autoimmune hemolytic anemia in treatment-naïve chronic hepatitis C infection.
    Srinivasan R.
    J Clin Gastroenterol; 2001 Mar 01; 32(3):245-7. PubMed ID: 11246355
    [Abstract] [Full Text] [Related]

  • 38. A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C.
    Ide T, Okamura T, Kumashiro R, Koga Y, Hino T, Hisamochi A, Ogata K, Tanaka K, Kuwahara R, Seki R, Sata M.
    Int J Mol Med; 2003 Jun 01; 11(6):729-32. PubMed ID: 12736713
    [Abstract] [Full Text] [Related]

  • 39. [Autoimmune hemolytic anemia caused by interferon?].
    Hinrichsen H, Schmidt WE.
    Dtsch Med Wochenschr; 1999 Mar 19; 124(11):339-40. PubMed ID: 10209537
    [No Abstract] [Full Text] [Related]

  • 40. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.
    Gergely AE, Lafarge P, Fouchard-Hubert I, Lunel-Fabiani F.
    Hepatology; 2002 May 19; 35(5):1281-2. PubMed ID: 11981781
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.